Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/16 09:06:37」(JST)

wiki en

Suplatast tosilate (INN) is a Th2 cytokine inhibitor^[1] which is used as an antiallergic drug. Often used in the treatment of Kimura's disease.^[2]^[3]

References

^ Tamaoki J, Kondo M, Sakai N et al. (July 2000). "Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group". Lancet 356 (9226): 273–8. doi:10.1016/S0140-6736(00)02501-0. PMID 11071181.
^ Ueda T, Arai S, Amoh Y, Katsuoka K (2011). "Kimura's disease treated with suplatast tosilate and loratadine". European Journal of Dermatology 21 (6): 1020–1. doi:10.1684/ejd.2011.1539. PMID 21914581.
^ Tsukagoshi H, Nagashima M, Horie T et al. (December 1998). "Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T)". Internal Medicine 37 (12): 1064–7. doi:10.2169/internalmedicine.37.1064. PMID 9932643.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 好酸球性胃腸炎 eosinophilic gastroenteritis

English Journal

Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.

Hashizume H, Umayahara T.
European journal of dermatology : EJD.Eur J Dermatol.2014 Apr 11. [Epub ahead of print]
PMID 24723649

Prophylactic Effectiveness of Suplatast Tosilate in Children with Asthma Symptoms in the Autumn: A Pilot Study.

Yoshihara S1, Yamada Y2, Fukuda H1, Tsuchiya T2, Ono M3, Fukuda N4, Kanno N5, Arisaka O1.Author information 1Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.2Tsuchiya Children's Hospital, Saitama, Japan.3Nogi Hospital, Tochigi, Japan.4Grimm Pediatric and Allergy Clinic, Tochigi, Japan.5Nishikata Hospital, Tochigi, Japan.AbstractBackground: Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however, the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previously, except for leukotriene receptor antagonists and Omalizmab. Methods: This study compared the prophylactic effectiveness of suplatast tosilate with that of mequitazine in children with asthma symptoms, which is usually exacerbated in the autumn. The study group comprised 27 children aged 2 to 15 years who required treatment for asthmatic attacks during the past year and tested positive at least for mite allergen in the preceding autumn. The subjects were randomly assigned to receive either suplatast or mequitazine. The primary endpoint of this study was the number of days without symptoms during the 8 weeks of treatment. In addition, the Japanese Pediatric Asthma Control Program (JPAC) scores were also recorded every 2 weeks in each group. Results: Overall, 14 patients received suplatast, and 13 received mequitazine for 8 weeks from September through early October. During follow-up, the number of days without symptoms and the total JPAC scores did not differ significantly between the groups. However, as compared with weeks 1 to 2 of treatment, the mean number of days without symptoms during weeks 7 to 8 increased significantly in only the suplatast group (8.6 vs. 11.5 days; p = 0.004). Conclusions: Our results suggest that short-term additional treatment with suplatast is useful for preventing asthma symptoms in children with asthma, which is usually exacerbated in the autumn.
Allergology international : official journal of the Japanese Society of Allergology.Allergol Int.2014 Feb 25. [Epub ahead of print]
Background: Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however, the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previously, except for leukotriene receptor antagonists and Omalizmab. Methods: This study compar
PMID 24561769

Four new polymorphic forms of suplatast tosilate.

Nagai K1, Ushio T2, Miura H3, Nakamura T4, Moribe K5, Yamamoto K5.Author information 1Taiho Pharmaceutical Co. Ltd., Ebisuno, Hiraishi, Kawauchi-cho, Tokushima 771-0194, Japan; Graduate School of Pharmaceutical Sciences, Chiba University, Inohana, Chuo-ku, Chiba 260-8675, Japan. Electronic address: kei-nagai@taiho.co.jp.2Ace Japan Co. Ltd., Higashine-koh, Higashine, Yamagata 999-3701, Japan.3Taiho Pharmaceutical Co. Ltd., Kamikawa-machi, Kodama-gun, Saitama 367-0241, Japan.4RIKEN, Wako, Saitama 351-0198, Japan.5Graduate School of Pharmaceutical Sciences, Chiba University, Inohana, Chuo-ku, Chiba 260-8675, Japan.AbstractWe found four new polymorphic forms (γ-, ε-, ζ-, and η-forms) of suplatast tosilate (ST) by recrystallization and seeding with ST-analogous compounds; three polymorphic forms (α-, β-, and δ-forms) of ST have been previously reported. The physicochemical properties of these new forms were investigated using infrared (IR) spectroscopy, solid-state nuclear magnetic resonance (NMR) spectroscopy, differential scanning calorimetry, and powder X-ray diffractometry. The presence of hydrogen bonds in the new forms was assessed from the IR and solid-state NMR spectra. The crystal structures of the ε- and η-forms were determined from their powder X-ray diffraction data using the direct space approach and the Monte Carlo method, followed by Rietveld refinement. The structures determined for the ε- and η-forms supported the presence of hydrogen bonds between the ST molecules, as the IR and solid-state NMR spectra indicated. The thermodynamic characteristics of the seven polymorphic forms were evaluated by determining the solubility of each form. The α-form was the most insoluble in 2-propanol at 35°C, and was thus concluded to be the most stable form. The ε-form was the most soluble, and a polymorphic transition from the ε- to the α-form was observed during solubility testing.
International journal of pharmaceutics.Int J Pharm.2014 Jan 2;460(1-2):83-91. doi: 10.1016/j.ijpharm.2013.10.049. Epub 2013 Nov 6.
We found four new polymorphic forms (γ-, ε-, ζ-, and η-forms) of suplatast tosilate (ST) by recrystallization and seeding with ST-analogous compounds; three polymorphic forms (α-, β-, and δ-forms) of ST have been previously reported. The physicochemical properties of these new forms were inve
PMID 24211359

Japanese Journal

症例トシル酸スプラタストとインドメタシンファルネシル内服併用を試みた木村病の1例

阿部真也,牛上敢,西部明子 [他]
皮膚科の臨床 57(4), 439-443, 2015-04
NAID 40020439794

トシル酸スプラタスト(IPD)内服が有効であった好酸球性膀胱炎の1例

倉本朋未,線崎博哉,稲垣武
泌尿器科紀要 = Acta urologica Japonica 60(9), 447-450, 2014-09
NAID 40020204087

トシル酸スプラタスト(IPD)内服が有効であった好酸球性膀胱炎の1例

倉本朋未,線崎博哉,稲垣武
泌尿器科紀要 = Acta urologica Japonica 60(9), 447-450, 2014-09
… Therefore, she was treated with a combination of corticosteroid and suplatast tolilate, followed by monotherapy with suplatast tolilate. … The relief of the symptoms by suplatast tolilate therapy continued for five months. … Therefore, she was treated with a combination of suplatast tosilate, anti-allergic drugs and mirabegron. … Fourteen months after treatment with suplatast tosilate, no disease progression was noted. …
NAID 120005477656

Related Pictures

★リンクテーブル★

リンク元	「スプラタスト」
拡張検索	「suplatast tosilate」

「スプラタスト」

Suplatast tosilate
Systematic (IUPAC) name
	(3-{[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino}-3-oxopropyl)(dimethyl)sulfonium 4-methylbenzenesulfonate
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Identifiers
CAS Registry Number	94055-76-2
ATC code	None
PubChem	CID: 71773
UNII	C9J89787U1
KEGG	D01423
ChEMBL	CHEMBL115435
Chemical data
Formula	C23H33NO7S2
Molecular mass	499.64 g/mol
	SMILES CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-] ;
(what is this?) (verify)